top of page

Off-Target Effects Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term

Apr 23

1 min read

He and Matt talk about portfolio construction, and the dynamics of taking on the right capital structure throughout different phases of a company's lifecycle. Neil shares early learnings from the commercial launch of Attruby, how being a commercial stage company can impact culture, and why he created the early-stage R&D focused sister company Gondola. Plus, discussing talent, intellectual property, and more.

https://vimeo.com/1185749084?share=copy&fl=sv&fe=ci

Chapters

The hub and spoke model - 0:41

Equity structure - 5:43

Putting together a portfolio - 9:08

Debt - 12:54

The Odyssey - 16:31

Building something sustainable - 18:21

Gondola - 30:43

Talent and culture - 32:25

Cost to IND - 36:42

Book recommendations - 40:07

Recent Posts

See All

Off-Target Effects Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his philosophy on running an investment firm

Off-Target Effects Episode 5: John Maraganore has been a champion of innovation throughout his career. He discusses the road to success at Alnylam, today's environment, and keeping the U.S. on top

Off-Target Effects Episode 4: Matt speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more